MBX Biosciences, Inc. MBX
Nov 4, 2026, 1:53 PM EST
- YTD
- +70.80%
- 1 year
- +161.25%
- Market cap
- 2.59B
- EPS (ttm)
- -2.37
- Shares out
- 48.16M
- Forward P/E
- -13.83
- YTD return
- +70.80%
- 1-year return
- +161.25%
- Volume
- 171.98K
- Avg volume
- 505.00K
- Open
- 56.21
- Previous close
- 55.00
- Day's range
- 51.73 – 57.00
- 52-week range
- 20.34 – 72.64
- Beta
- 0.18
- Analysts
- Strong Buy
- Price target
- 95.70 (+77.6%)
- Earnings date
- Nov 5, 2026
1Y +31.24 (+138.54%)
Key statistics
- Enterprise value
- 2.20B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -53.01M
- Total cash
- 418.58M
- Total debt
- 3.34M
- Return on equity
- -33.17%
- Short % of float
- 12.83%
- 50-day average
- 57.58
- 200-day average
- 45.65
Analyst view
Consensus: strong buy
- Target (low)
- 80.00
- Target (mean)
- 95.70
- Target (high)
- 150.00
- Strong buy3
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.84465.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.82675 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.63251 | -0.78 | -0.15 | -23.32% |
| May 7, 2026 | Mar 31, 2026 | -0.62 | -0.51 | +0.11 | +17.74% |
| Mar 12, 2026 | Dec 31, 2025 | -0.64 | -0.49 | +0.15 | +23.44% |
| Nov 6, 2025 | Sep 30, 2025 | -0.73 | -0.63 | +0.10 | +13.70% |
| Aug 7, 2025 | Jun 30, 2025 | -0.77 | -0.58 | +0.19 | +24.68% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Stifel | main | Buy | Buy |
| Oct 2, 2026 | Guggenheim | main | Buy | Buy |
| Aug 10, 2026 | Truist Securities | main | Buy | Buy |
| Jul 29, 2026 | Mizuho | main | Outperform | Outperform |
| May 12, 2026 | Barclays | main | Overweight | Overweight |
| May 12, 2026 | Citizens | main | Market Outperform | Market Outperform |
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mbxbio.com
News
Microbix Attending & Presenting at IPVS 2026 
MBX Biosciences to Participate in Upcoming November Investor Conferences 
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84 
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150 
MBX Biosciences (NASDAQ:MBX) Shares Climb 4.1% – Time to Buy? 
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday 
MBX Biosciences, Inc. $MBX Shares Newly Bought by Bank of America Corp DE 
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) 
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Your note
Sign in to keep a note on MBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AZOULAY SALOMON M.D. | Officer | Sale | Aug 3, 2026 | 14,399 |
| BARTRAM RICHARD B | Chief Financial Officer | Stock Award(Grant) | Feb 1, 2026 | 15,000 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 17, 2025 | 0 |
| HAWRYLUK P KENT | Chief Executive Officer | Sale | May 5, 2026 | 1,214,440 |
| HERON PATRICK J | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 25, 2025 | 0 |
| HOERTER STEVEN L | Chief Executive Officer | Stock Award(Grant) | Aug 2, 2026 | 102,938 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 13.81% | 6,652,013 | 365.86M | Jun 29, 2026 |
| FMR, LLC | 11.05% | 5,322,885 | 292.76M | Jun 29, 2026 |
| Wellington Management Group, LLP | 10.34% | 4,977,523 | 273.76M | Jun 29, 2026 |
| NEA Management Company, LLC | 7.51% | 3,614,486 | 198.80M | Jun 29, 2026 |
| Orbimed Advisors LLC. | 7.12% | 3,428,736 | 188.58M | Jun 29, 2026 |
| Blackrock Inc. | 6.90% | 3,323,672 | 182.80M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.36% | 1,135,375 | 62.45M | Jun 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.81% | 873,492 | 48.04M | Jun 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.70% | 817,600 | 44.97M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.67% | 805,557 | 44.31M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.41% | 680,000 | 37.40M | Aug 30, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.40% | 674,700 | 37.11M | Aug 30, 2026 |